From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Polymetal, PZ Cussons & the art of RNS disclosures

By Chris Bailey | Thursday 18 April 2019


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


A couple of corporate names I own published regulatory news statements this morning. Polymetal (POLY) - which I most recently wrote about here - published its first quarter production numbers. I thought they read well and included a gold equivalent production growth of +27% year-on-year, confirmed key corporate projects such as Pox-2 moves on apace and overall reiterated its full year outlook. As I noted in the above linked piece, all eyes on the upcoming capital markets day later this month and here at/around eight quid a share I rate it as a buy…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:


Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

Gold

Sprott bullish on gold

 

SOS

Sosandar: when is the warning?

 

SCGL

Evil Banksta: TW schoolboy error

 

ARB

Worthless Argo what news Helios?

Sunday »

Bearcast

Tom Winnifrith Bearcast: macrobabble calls

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 18:00:11